Downregulation of ADAMTS18 May Serve as a Poor Prognostic Biomarker for Cervical Cancer Patients.
ADAMTS18 is a member of ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family proteins which have been found to play important roles in cancer progression and metastasis in different cancer types. The present study aims at evaluating the prognostic significance of ADAMTS18 in cervical cancer. The expression levels of ADAMTS18 was evaluated by real-time PCR in normal (N=28) and cervical cancer tissues from patients at different stages as well as in tumor tissues from 35 cervical cancer patients with primary cancer and 29 patients with metastasis. The correlation between serum ADAMTS18 expression levels and clinicopathologic features or overall survival of cervical cancer patients was analyzed. ADAMTS18 expression levels were significantly decreased in cervical cancer tissues compared with normal tissues and it decreased gradually from early stage to late stage. Low expression of ADAMTS18 was positively associated with high tumor stage (P=0.0239), positive lymph node metastasis (P=0.0388), and distant metastasis (P=0.0004). Tissue levels of ADAMTS18 in patients with primary cancer were significantly lower compared with those with metastasis. Moreover, patients with low ADAMTS18 expression levels had shorter overall survival (P=0.0119) or disease-free survival (P=0.0033). Multivariate analysis demonstrated that ADAMTS18 was an independent prognostic factor for cervical cancer. Our study suggests that ADAMTS18 is downregulated in cervical cancer and ADAMTS18 may serve as a potential prognostic biomarker for cervical cancer.